HomeCompareTAIPY vs GBDC

TAIPY vs GBDC: Dividend Comparison 2026

TAIPY yields 14.29% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.74M in total portfolio value
10 years
TAIPY
TAIPY
● Live price
14.29%
Share price
$14.00
Annual div
$2.00
5Y div CAGR
-8.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.1K
Annual income
$1,041.05
Full TAIPY calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — TAIPY vs GBDC

📍 GBDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTAIPYGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TAIPY + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TAIPY pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TAIPY
Annual income on $10K today (after 15% tax)
$1,214.29/yr
After 10yr DRIP, annual income (after tax)
$884.89/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,929,989.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TAIPY + GBDC for your $10,000?

TAIPY: 50%GBDC: 50%
100% GBDC50/50100% TAIPY
Portfolio after 10yr
$10.41M
Annual income
$8,195,152.22/yr
Blended yield
78.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

TAIPY
No analyst data
Altman Z
13.5
Piotroski
6/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TAIPY buys
0
GBDC buys
0
No recent congressional trades found for TAIPY or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTAIPYGBDC
Forward yield14.29%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-8.8%51.1%
Portfolio after 10y$37.1K$20.78M
Annual income after 10y$1,041.05$16,389,263.41
Total dividends collected$12.4K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: TAIPY vs GBDC ($10,000, DRIP)

YearTAIPY PortfolioTAIPY Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$12,003$1,302.86$12,490$1,790.28$487.00GBDC
2$14,176$1,332.88$16,522$3,157.73$2.3KGBDC
3$16,510$1,341.75$23,578$5,898.68$7.1KGBDC
4$18,998$1,331.92$37,115$11,886.75$18.1KGBDC
5$21,634$1,306.29$66,136$26,423.57$44.5KGBDC
6$24,416$1,267.90$137,257$66,491.44$112.8KGBDC
7$27,345$1,219.66$341,734$194,868.54$314.4KGBDC
8$30,423$1,164.26$1,050,788$685,133.02$1.02MGBDC
9$33,657$1,104.05$4,099,314$2,974,971.01$4.07MGBDC
10$37,054$1,041.05$20,775,530$16,389,263.41$20.74MGBDC

TAIPY vs GBDC: Complete Analysis 2026

TAIPYStock

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.

Full TAIPY Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this TAIPY vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TAIPY vs SCHDTAIPY vs JEPITAIPY vs OTAIPY vs KOTAIPY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.